billHR9044Event Tuesday, May 26, 2026Analyzed

To amend title V of the Public Health Service Act to reauthorize the Minority Fellowship Program.

Neutral

Summary

HR9044 reauthorizes the Minority Fellowship Program under the Public Health Service Act, but it is a procedural authorization without specified funding. The bill is in early legislative stages (referred to committee) and has no near-term market impact.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR9044 is a procedural reauthorization with no funding specified.
  • 2.The Minority Fellowship Program is a small grant program unlikely to affect major healthcare companies.
  • 3.The bill is in early stage; no market catalysts from this legislation.

Market Implications

The bill has no direct market implications. Healthcare sector companies such as $UNH, $CNC, and $MOH are not materially affected by a small fellowship program. Investors should focus on broader healthcare policy developments with fiscal impact.

Full Analysis

HR9044 was introduced on May 26, 2026, and referred to the House Committee on Energy and Commerce. The bill amends Title V of the Public Health Service Act to reauthorize the Minority Fellowship Program, which provides grants to support minority individuals pursuing graduate degrees in behavioral health fields. As an authorization bill, it sets policy but does not appropriate any specific funds—actual spending requires a separate appropriations bill. The legislation is in its earliest stage with no committee markup or floor action. The program is small in scale compared to major healthcare spending, and no direct revenue streams for publicly traded companies are identifiable. The bill has no discernible impact on healthcare sector financials. Legislative momentum is low given its procedural status and lack of senior sponsor momentum (sponsor Rep. Watson Coleman is a junior member). Investors should monitor for committee action and subsequent appropriations, but no near-term market effects are expected.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.